key: cord-0844476-301dgfpx
authors: Mangin, Dee; Howard, Michelle
title: The use of inhaled corticosteroids in early-stage COVID-19
date: 2021-08-10
journal: Lancet
DOI: 10.1016/s0140-6736(21)01809-2
sha: 5ac0d15450a5722937be0824f1f4ad14e1de362c
doc_id: 844476
cord_uid: 301dgfpx

nan

The desperation of clinicians when faced with COVID-19 and the dearth of therapeutic options for its treatment have led clinical practice to reach for last-resort approaches, supported by tenuous data or hypotheses. The need for data-based clinical practice is clear from the initial wide use of hydroxychloroquine, shown subsequently to be harmful, 1,2 and the initial avoidance of oral corticosteroids, shown subsequently to be beneficial. 3 Now practice is changing toward the usual measured approach of gathering data and using restraint, trying above all to do no harm in this viral illness.

Platforms for remarkable well designed pragmatic pandemic research, such as PRINCIPLE and the earlier RECOVERY study platform, have emerged to inform practice. The focus of the PRINCIPLE adaptive trial platform on management of COVID-19 in the primary care setting is vital-less than 10% of patients are managed in hospital.

Early in the pandemic, epidemiological data showing that patients with chronic obstructive pulmonary disease (COPD) and asthma had a lower incidence of COVID-19 infection led to speculation that inhaled corticosteroids could have some benefit. A small openlabel trial suggested possible benefit in patients not admitted to hospital. 4 Although there is a plausible mechanism for why inhaled corticosteroids could be beneficial, there are two reasons to be cautious: in the RECOVERY trial, although oral steroids offered benefit in seriously ill patients, they offered no benefit and possibly harm in those with less serious illness. 3 And for those with COPD and asthma who do get infected, population studies suggest that use of inhaled corticosteroids is associated with worse outcomes. 5,6 These inconsistent results leave primary care practitioners, heavily involved in care of high-risk patients with early-stage COVID-19 in the community, with little certainty of the potential benefits and harms of inhaled corticosteroids.

A new analysis of the PRINCIPLE trial by Ly-Mee Yu and colleagues 7 reported in The Lancet provides data from the largest trial of the use of inhaled corticosteroids in early-stage COVID-19. The primary outcome population included 833 participants who received inhaled budesonide plus usual care and 1126 who received usual care alone. The mean age was 64·2 years (SD 7·6), 1805 (92%) of 1959 participants were White, 1015 (52%) were women, and 1581 (81%) had comorbidities. The initial trial primary outcome was hospital admission or death, but this was changed before analysis because of lower than expected UK hospital admission rates (although the rate of hospital admissions or death in the trial was higher than the 5% estimated for the sample size calculation). Time to first selfreported recovery was added as a coprimary outcome. The results showed that using inhaled corticosteroids early in COVID-19 in patients aged 65 years and older and those aged 50 years and older with comorbidities shortened the time to first self-reported recovery by an estimated median of 2·94 days (95% Bayesian credible interval [BCI] 1·19-5·11), with an estimated time of 11·8 days (95% BCI 10·0-14·1) in the budesonide group versus 14·7 days (12·3-18·0) in the usual care group. The hospital admission or death outcome did not achieve the prespecified superiority threshold in the primary analysis population (72 [9%] of 787 in the budesonide group vs 116 (11%) of 1069 in the usual care group; model estimate 6·8% [95% BCI 4·1-10·2] vs 8·8% [5·5-12·7], odds ratio 0·75 [95% BCI 0·55-1·03]). The possibility of bias in the self-reported recovery outcome cannot be ruled out-placebos were not used and given that the primary and other secondary outcomes use self-report questions that are largely not based on instruments previously tested for reliability or validity, the well described placebo effect of inhalers could have inflated the effect size.

There remain puzzling questions about the doseresponse and mechanisms of effect of inhaled corticosteroids in reducing time to self-reported recovery: in the patient group with less severe illness, the RECOVERY trial showed that use of systemic steroids appeared to result in worse outcomes than placebo, yet the dose of inhaled corticosteroids in the PRINCIPLE study is high enough to have systemic absorption. The data presented on differences in the effect of inhaled corticosteroids on individual symptoms are interesting: notably, the difference between groups was greater for gastrointestinal symptoms and myalgia than for respiratory symptoms as might have been anticipated. Also notable were the findings that the between-group difference in global self-rating of how well patients felt had largely disappeared by day 28 and the time to alleviation of all symptoms was not different between groups, yet the difference in the WHO-5 Well-Being Index, a subjective psychological wellbeing scale, was still present at 28 days. Longer-term followup clarifying the effects on the trajectory of illness, especially on persistent morbidity after COVID-19, would be useful.

On the basis of the PRINCIPLE trial data, it seems reasonable to consider inhaled corticosteroid use in early COVID-19 in patients similar to the trial population group (people with ongoing symptoms from COVID-19 aged ≥65 years or ≥50 years with specific comorbidities) who are interested in using them (80% of participants in the inhaled budesonide group in PRINCIPLE used the inhaled corticosteroids for at least a week). Various subgroup analyses in PRINCIPLE do not provide any pointers to which particular patient or illness characteristics in the included population might be more likely to predict benefit. These trial data do not support use in younger populations who are at lower risk of complications (<65 years with no comorbidities or anyone <50 years). Because vaccination was uncommon in trial participants, an important question is whether and what effect would be seen in the fully vaccinated population who have a different illness severity and trajectory.

We see through two recent pragmatic COVID-19 treatment trial platforms an important shift in approach: trials funded by governments and not industry, answering the crucial questions driven by immediate clinician need and not product marketing, and providing data in the spaces of clinical equipoisethis importance should not be underestimated or lost.

We declare no competing interests.

*Dee Mangin, Michelle Howard mangind@mcmaster.ca

Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: a randomized clinical trial

Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology. Pharmacovigilance memorandum. Hydroxychloroquine and chloroquine: all adverse events in the setting of COVID-19

Dexamethasone in hospitalized patients with COVID-19

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform

Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial